Rigel Pharmaceuticals, Inc. (RIGL) has kicked off 2025 with strong financial results, delivering a profitable first quarter on the back of rising product sales and strategic pipeline investments.
Rigel is a commercial-stage biotech company focused on hematologic disorders and cancer. Its marketed therapies include TAVALISSE, GAVRETO, and REZLIDHIA, targeting conditions such as immune thrombocytopenia, RET-altered cancers, and relapsed/refractory AML, respectively.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.